ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0797

Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis

Michal Doumen1, Diederik De Cock1, Sofia Pazmino1, Delphine Bertrand1, Rene Westhovens2 and Patrick Verschueren3, 1KU Leuven, Leuven, Belgium, 2University Hospitals KU Leuven, Maaseik, Belgium, 3University Hospitals Leuven - KULeuven, Leuven, Belgium

Meeting: ACR Convergence 2021

Keywords: Disease Activity, Patient reported outcomes, psychological status, psychosocial factors, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Patient-reported outcomes (PROs) relating to global psychosocial wellbeing are rarely assessed in clinical trials for rheumatoid arthritis (RA), and specifically not to tailor additional interventions. Moreover, many patients with RA report ongoing pain, fatigue and suboptimal mental health despite satisfactory clinical disease control. We aimed to describe the association of early psychosocial wellbeing, coping and illness perceptions with sustained remission in early RA, and to identify patients with psychosocial unmet needs despite being in clinical remission.

Methods: Data were analysed from the 2-year randomised controlled treat-to-target trial Care in early RA (CareRA). Patients completed the Short Form 36 (SF-36), Revised Illness Perception Questionnaire (IPQ-R) and Utrecht Coping List (UCL) among other PROs. Sustained remission was defined as continued DAS28-CRP < 2.6 from week 16 to week 104. SF-36 mental components, UCL and IPQ-R at baseline and week 16 were studied as predictors of sustained remission with multivariate logistic regression adjusting for age, gender, treatment arm, serology and 2-component DAS28 (1). Subgroups of patients in remission at week 16 were identified by Latent Profile Analysis (LPA) including significant psychosocial predictors from the regression models. Survival of remission was compared per subgroup by Kaplan-Meier analysis and Cox proportional hazards regression.

Results: All 379 included patients were recently diagnosed with RA and had not received DMARDs before study initiation. Most patients were women (69%) and RF/ACPA-positive (66%), with a mean age of 52 (SD 13) years. Sustained DAS28 CRP-remission was achieved by 124/379 (33%) patients. Sustained remission was associated with higher SF-36 scores and less passive coping at baseline, and with higher SF-36 scores and more positive IPQ-R reports at week 16 (Table 1). Among patients in DAS28-CRP remission at week 16 (n=287), two subgroups were identified: a low-psychosocial-burden (n=231) and a high-psychosocial-burden group (n=56) (Fig. 1). The low-psychosocial-burden group retained remission longer (HR 0.51 [0.35-0.73]) (Fig. 2).

Conclusion: Suboptimal psychosocial wellbeing and illness perceptions were associated with lower odds of sustained remission in an early RA trial. Illness perceptions appeared to be more clinically relevant after 4 months of treatment. One-in-five patients still showed worse psychosocial outcomes despite being in early clinical remission, and these patients tended to lose remission earlier. Future research should focus on timely identification of unmet needs and person-centred interventions to target them.

(1) Hensor EMA, et al. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatol (Oxford). 2019;58(8):1400–9

Table 1. Psychosocial variables at baseline and week 16 predicting sustained remission.
Results were obtained from multivariate logistic regression models with the specified variables as predictors and the odds of sustained DAS28-CRP-remission (from week 16 to week 104) as the dependent variable. All models contained age, gender, treatment arm, the presence of autoantibodies and 2C-DAS28 as covariates. OR = odds ratio, CI = confidence interval; SF_36 = Short Form 36, MCS = mental component score, VT = vitality, SF = social function, MH = mental health, RE = role emotional; IPQ-R = Revised Illness Perception Questionnaire; UCL = Utrecht Coping List; 2C-DAS28 = two-component Disease Activity Score in 28 joints

Figure 1. Clustering of patients in DAS28-CRP remission at week 16 by LPA of psychosocial variables.
Results of latent profile analysis (LPA) of patients in DAS28-CRP remission at week 16, based on 9 psychosocial variables. Optimal model fit was obtained for 2 classes with equal variances and equal covariances. Class 1 consists of 231/287 patients (80%) and class 2 of 56/287 patients (20%). IPQ-R = Revised Illness Perception Questionnaire; SF36 = Short Form 36, VT = vitality, SF = social function, MH = mental health, RE = role emotional

Figure 2. Kaplan-Meier (KM) curves for survival of DAS28-CRP remission, stratified by psychosocial class of patients in DAS28-CRP remission at week 16.


Disclosures: M. Doumen, None; D. De Cock, None; S. Pazmino, None; D. Bertrand, None; R. Westhovens, galapagos, 12, advisory board and principal investigator, gilead, 1, celltrion, 1; P. Verschueren, Pfizer, 12, Holder of the Pfizer Chair Early Rheumatoid Arthritis Management at the KU Leuven, Eli Lilly, 2, Nordic Pharma, 2, galapagos, 2, gilead, 2, ABBVIE, 2, Celltrion, 2, BMS, 2.

To cite this abstract in AMA style:

Doumen M, De Cock D, Pazmino S, Bertrand D, Westhovens R, Verschueren P. Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/psychosocial-wellbeing-and-illness-perceptions-during-the-early-disease-phase-predict-sustained-remission-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psychosocial-wellbeing-and-illness-perceptions-during-the-early-disease-phase-predict-sustained-remission-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology